Підготовка до КРОК онлайн – бали БПР для студентів і лікарів. Готуйтеся до КРОК онлайн з інтерактивними тестами та вебінарами БПР – офіційний провайдер БПР №2732.
Каталог курсів і тестів для підготовки до КРОК · Каталог вебінарів БПР з балами
Питання КРОК 1 (медицина) · тест з варіантами та поясненням · Medus
EN: Immunology Cancer immunotherapy (immune-oncology) loosely echoes the radical therapy developed by William Coley in the late 19th century, in which he injected bacteria into cancer patients. Modern immunotherapy focuses on "educating" and boosting a body’s immune system so that it can recognize and attack cancer cells. Natural killer cells (a type of white blood cell are harnessed to identify and target infected cells. In 1975, two biochemists - Cesar Milstein and Georges Kohler - laid the foundations for using antibodies as a means to destroy cancer cells. Antibodies are protein molecules made by B-cells, which are a type of lymphocyte. They bind to molecules (antigens) on the surface of targeted cells, such as bacteria, and signal to the immune system to destroy them. Milstein and Kohler found a way to stimulate B-cells to produce unlimited numbers of one specific type of antibody (monoclonal antibodies). The next step was to develop them to target cancer cells, a technique now used in the diagnosis and treatment of some cancers. The quest for immunotherapy with a greater reach has continued into the early 21st century. Much contemporary research focuses on T-cells, another type of lymphocyte. The role of killer T-cells is to travel around the body finding and destroying defective cells. When someone comes in contact with an infection, the body makes T-cells to fight that specific disease. After T-cells have performed their search-and-destroy mission, the body keeps a few of them in reserve, in case the same infection reoccurs. However, even though T-cells are good at fighting infections, they find it hard to identify cancer cells as "enemies". During the 1980s, American immunologist James P. Allison and his Japanese counterpart Tasuku Honjo, had discovered the chemical mechanism T-cells use to, recognize "hostile"infection cells and realized their potential to identify cancer cells. In 2002, researchers used CAR (chimeric antigen receptor) T-cells to destroy prostate cancer cells in a laboratory experiment. After successful clinical trials, CAR T-cells are now used to fight certain kinds of leukaemia and lymphoma cancers. Choose the correct statement:
T-клітини з труднощами розпізнають ракові клітини як «ворогів»
EN: T-cells struggle to identify cancer cells as "enemies"
Ракові клітини часто виражають мало або не виражають MHC I, що ускладнює розпізнавання їх цитотоксичними T-клітинами. Додатково ракові клітини можуть пригнічувати імунну відповідь через молекули контрольних точок. Моноклональні антитіла виробляються гібридомами, NK-клітини не є еритроцитами, а CAR T-терапія розвинулася значно пізніше 1950-х років.
EN: Cancer cells often express little or no MHC I, making it difficult for cytotoxic T-cells to recognize them. Additionally, cancer cells can suppress immune responses through checkpoint molecules. Monoclonal antibodies are produced by hybridomas, NK cells are not erythrocytes, and CAR T-cell therapy developed significantly later than the 1950s.